ClinicalTrials.gg
Active, not recruitingNCT07074977CPUOUpdated Jul 27, 2026

Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)

A Phase 2 interventional study of nemolizumab and Placebo in Chronic Pruritus of Unknown Origin, sponsored by Galderma R&D. Active, not recruiting at 26 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 163 studies in Pruritus with a site in United States — 24 open to participants now, 28 under way, 8 of them phase 3. Pruritus · United States.

Planned enrollment
95th of 153
50 · median 70
Started
2025
with 10 others
Phase 2
60 of 163
6 open now
Primary completion
2026-12
later than 4 of 27 live
Registered
149th of 163
by date
Lead sponsor
4 of 163
Galderma R&D

Among the 163 studies in Pruritus with a site in United States, this one is the 95th largest by planned enrollment of the 153 interventional ones that give a count, is one of 11 that started in 2025, is one of 60 in phase 2, reaches primary completion later than 4 of the 27 other live ones, and was the 149th registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

24 of the 163 studies in Pruritus with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies in Pruritus with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the PK/PD relationship of nemolizumab in adult participants aged 18 years or above with chronic pruritus of unknown origin (CPUO) during a 16-week treatment period.

Read the detailed description

This study is to assess the PK/PD relationship of nemolizumab in adult participants with CPUO. The study will consist of a 2 to 4-week screening period, a 16-week treatment period, and an 8-week follow up period (12 weeks after last study drug injection). Participants will be randomized 4:1 to nemolizumab or placebo. Dosing will be adjusted according to participants body weight ( less than [\<] 90 kilograms [kg] versus >= 90 kg). Participation in the study will last up to 28 weeks.

03

Conditions studied

  • Chronic Pruritus of Unknown Origin

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are eligible to be included in the study only if all of the following criteria apply:

    1. Participant must be 18 years of age or older.
    2. Participants with chronic pruritus on normal-appearing skin (except for dry skin or excoriations) for at least 6 months before the screening visit.
    3. Chronic pruritus considered of unknown origin (i.e., without a clear association to another condition or medication) as assessed by the investigator at baseline.
    4. The pruritus must affect at least 4 of the following body areas: left lower limb, right lower limb, left upper limb, right upper limb, anterior trunk, posterior trunk.
    5. History of insufficient control of the chronic pruritus with prior treatment.
    6. Peak Pruritus Numeric Rating Scale (PP NRS) score greater than and equal to (>=) 7 in the 24-hour period prior to the Screening visit.
    7. Weekly average Peak Pruritus Numeric Rating Scale (PP NRS) score >= 7 in the week (7 days) immediately prior to randomization, as recorded in the patient diary.
    8. Female of must agree to use at least 1 adequate and approved method of throughout the study and for 12 weeks after the last study intervention injection.

      Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    9. Females of non-childbearing potential must meet 1 of the following criteria:
  • Absence of menstrual bleeding for 1 year prior to screening without any other medical reason, confirmed with follicle stimulating hormone (FSH) level in the range
  • Documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy at least 3 months before screening 10. Signed . 11. Participant is willing and able to comply with all of the time commitments and procedural requirements of the clinical study protocol.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply :

Medical Conditions

  1. Known dermatologic, systemic, neurologic or psychiatric condition(s), other than dry skin, that considered by the investigator to be the primary cause of current pruritus.
  2. Documented parasitic infection, including skin parasites such as scabies, within 12 weeks prior randomization.
  3. Cutaneous infection within 1 week before the baseline visit, any infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics, or antifungals within 2 weeks before the baseline visit.
  4. Diagnosis of chronic pruritus of neuropathic origin including but not limited to scalp dysesthesia, brachioradial pruritus, generalized neuropathic pruritus or chronic pruritus of psychogenic origin (pruritus associated with psychological disorders such as delusional parasitosis or Morgellons disease).
  5. Any medical or psychological condition or any laboratory abnormalities that put the participant at significant risk.
  6. History of bullous pemphigoid or positive bullous pemphigoid autoantibodies at screening.
  7. History of mastocytosis or serum total tryptase greater than (>) 20 nanograms per milliliter (ng/ml) at screening.
  8. Active tuberculosis (TB) or non-tuberculosis mycobacterial infection, or a history of incompletely treated TB.
  9. Positive serology results surface antigen or (HBsAg) or Antibody to Hepatitis B core antigen (HBcAb), virus (HCV) antibody with positive confirmatory test for HCV (e.g., polymerase chain reaction [PCR]), or [HIV] antibody) at the screening visit.
  10. Known or suspected immunodeficiency.
  11. Lymphoproliferative disease or within the last 5 years.
  12. Presence of major psychiatric diagnosis, clinically significant dementia, intellectual impairment, or any medical condition or disability which, in the investigator's opinion, may confound the assessment of nemolizumab's safety or efficacy or interfere with the participant's ability to comply with protocol mandated activities.
  13. Receipt of prohibited medications within the specified timeframe before the baseline visit
  14. Previous participation in a clinical study with nemolizumab
  15. Currently participating or participated in any other study of an drug or device, within the past 8 weeks (or 5 half-lives of the investigational drug, whichever is longer) before the screening visit, or is in an exclusion period (if verifiable) from a previous study.
  16. Body weight \< 30 kg.
  17. Prior treatment with commercially available nemolizmab
  18. to the active substance (nemolizumab) or to any of the of the study intervention.
  19. Requiring rescue therapy for pruritus during the screening period.
  20. Alcohol or substance abuse within 6 months of the screening visit.
  21. Planned or anticipated major surgical procedure or other activity that would interfere with the participant's ability to comply with protocol-mandated assessments.
  22. Pregnant or breastfeeding female, or female planning a pregnancy during the study.
  23. Vulnerable participant as defined by International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    nemolizumab

    Participants weighing \< 90 kg will receive one subcutaneous (SC) injection of 30 milligrams (mg) nemolizumab (with 60 mg loading dose at baseline) every 4 weeks (Q4W) at Weeks 4, 8, and 12. Participants weighing \>= 90 kg will receive two SC injections of 30 mg nemolizumab ( 60 mg total) at baseline (without loading dose) and at Weeks 4, 8, and 12.

    Drug: nemolizumab

  • Placebo comparator
    Placebo

    Participants weighing \< 90 kg will receive two SC injections of matching placebo at baseline followed by 1 SC injection Q4W at Weeks 4, 8 and 12. Participants weighing \>= 90 kg will receive two SC injections of matching placebo at baseline and at Weeks 4, 8, and 12.

    Drug: Placebo

Interventions

  • Participants will receive either 30 mg or 60 mg dose of nemolizumab as SC injection.

    Also known as: CD14152

  • DrugPlacebo

    Participants will receive matching placebo as SC injection.

06

What researchers measure

Primary outcomes

  1. Population Pharmacokinetics (PopPK) Model of the Elimination of nemolizumab During the 16-week Treatment Period Point

    Point Estimate of Population Total Clearance (Cl/F) of nemolizumab will be reported.

    Time frame: From Baseline up to Week 16

  2. Population Pharmacokinetics (PopPK) Model of the Distribution of nemolizumab During the 16-week Treatment Period Point

    Point Estimate of Population Volume of Distribution (Vd/F) of nemolizumab will be reported.

    Time frame: From Baseline up to Week 16

  3. Population Pharmacokinetics (PopPK) Model of the Absorption of nemolizumab During the 16-week Treatment Period Point

    Point Estimate of Absorption Rate Constant (Ka) of nemolizumab will be reported.

    Time frame: From Baseline up to Week 16

  4. Pharmacokinetic (PK)/Pharmacodynamic (PD) Model of the Effect of nemolizumab Systemic Exposure on Pruritus during 16-week Treatment Period

    Point Estimate of population IC50 of nemolizumab, i.e. the drug concentration required to produce 50% of the maximal inhibition of Average Peak Pruritus, will be reported.

    Time frame: From Baseline up to Week 16

Secondary outcomes

  1. Individual Observed Ctrough Concentrations of nemolizumab

    Average of individual observed Ctrough concentrations of nemolizumab at week 16 will be reported.

    Time frame: Week 16

  2. Individual Model - derived Ctrough Concentrations of nemolizumab

    Average of individual model-derived Ctrough concentrations of nemolizumab at week 16 will be reported.

    Time frame: Week 16

  3. Individual Total Clearance (Cl/F) of nemolizumab

    Average of individual model-derived estimates of Cl/F will be reported.

    Time frame: From Baseline up to Week 16

  4. Individual Volume of Distribution (Vd/F) of nemolizumab

    Average of individual model-derived estimates of Vd/F will be reported.

    Time frame: From Baseline up to Week 16

  5. Individual Absorption Rate Constant (Ka) of nemolizumab

    Average of individual model-derived estimates of Ka will be reported.

    Time frame: From Baseline up to Week 16

  6. Individual Maximum Serum Concentration (Cmax) of nemolizumab

    Average of individual model-derived estimates of Cmax will be reported.

    Time frame: From Baseline up to Week 16

  7. Individual Time to Reach Maximum Serum Concentration (Tmax) of nemolizumab

    Average of individual model-derived estimates of Tmax will be reported.

    Time frame: From Baseline up to Week 16

  8. Individual Area Under the Concentration-time Curve Within a Dosing Interval (AUCtau) of nemolizumab

    Average of individual model-derived estimates of AUCtau will be reported.

    Time frame: From Baseline up to Week 16

  9. Terminal Half-life (t1/2) of nemolizumab

    Average of individual model-derived estimates of t1/2 will be reported.

    Time frame: From Baseline up to Week 16

  10. Change From Baseline in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS)

    PP NRS is a scale that will be used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores are provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicate worse outcome. Participant will report PP NRS via daily e-PRO diary.

    Time frame: Up to Week 16

  11. Number of Participants With Adverse Events (AEs), Treatment Emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESIs), and Serious Adverse Events (SAEs), AEs Leading to Study Intervention Withdrawal, AEs Leading to Study Discontinuation

    AE defined as any untoward medical occurrence in clinical study participant administered a medicinal product which does not necessarily have causal relationship with this treatment. TEAEs defined as AEs occurring after first administration of study drug during the study. SAE was any untoward medical occurrence, in view of either Investigator or Sponsor, that resulted in death, was life-threatening, resulted in inpatient hospitalisation or prolongation of existing hospitalisation, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect or was important medical event. AESI was noteworthy TEAE for study drug that was to be monitored closely and reported promptly. Relatedness to study drug was based on Investigator's discretion. AEs Leading to study treatment withdrawal and AEs Leading to study withdrawal will also be reported.

    Time frame: From start of study up to follow-up period (Week 24)

07

Study locations

26 sites
  • Galderma Investigational Site (site# 8893)
    Birmingham, Alabama 35244, United States
  • Galderma Investigational Site (#8768)
    Tucson, Arizona 85718, United States
  • Galderma Investigational Site (site# 8636)
    Fountain Valley, California 92708, United States
  • Galderma Investigational Site (site# 8130)
    Los Angeles, California 90045, United States
  • Galderma Investigational Site (#9975)
    Sacramento, California 95815, United States
  • Galderma Investigational Site (site# 8021)
    San Diego, California 92123, United States
  • Galderma Investigational Site (site# 7075)
    San Francisco, California 94115, United States
  • Galderma Investigational Site (site# 8608)
    Santa Monica, California 90404, United States
  • Galderma Investigational Site (#8295)
    Miami, Florida 33136, United States
  • Galderma Investigational Site (site# 7054)
    Tampa, Florida 33609, United States
  • Galderma Investigational Site (site# 8142)
    Indianapolis, Indiana 46250, United States
  • Galderma Investigational Site (#7129)
    Bowling Green, Kentucky 42104, United States
  • Galderma Investigational (Site# 7048)
    Baltimore, Maryland 21201, United States
  • Galderma Investigational Site (site# 8743)
    Ann Arbor, Michigan 48109, United States
  • Galderma Investigational Site (site# 8521)
    Saint Joseph, Missouri 64506, United States
  • Galderma Investigational Site (site# 8108)
    Las Vegas, Nevada 89145, United States
  • Galderma Investigational Site (site# 7110)
    New City, New York 10956, United States
  • Galderma Investigational Site (#7130)
    The Bronx, New York 10455, United States
  • Galderma Investigational Site (site# 7111)
    Fargo, North Dakota 58103, United States
  • Galderma Investigational Site (#8212)
    Portand, Oregon 97210, United States
  • Galderma Investigational Site (#8255)
    Philadelphia, Pennsylvania 19103, United States
  • Galderma Investigational (Site # 7131)
    Spartanburg, South Carolina 29307, United States
  • Galderma Investigational Site (site# 8003)
    Webster, Texas 77598, United States
  • Galderma Investigational Site (site# 8862)
    Fairfax, Virginia 22031, United States
  • Galderma Investigational Site (site# 8725)
    Morgantown, West Virginia 26505, United States
  • Galderma Investigational Site (site# 8045)
    Québec, Quebec G1V 4X7, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.

Of 37 industry-sponsored phase 2 interventional studies under Pruritus, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 21. This study's planned 14 months is close to that.

Counting every sponsor, half of 52 studies reached it within 16 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2025
First posted
Jul 20, 2025
StartActual
Oct 20, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Jan 2027
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07074977
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Jul 20, 2025
Start date
Oct 20, 2025
Primary completion
Dec 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Jul 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nemolizumab

Start the discussion